Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Average Rating of “Moderate Buy” by Analysts

Alphatec Holdings, Inc. (NASDAQ:ATEC) has earned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $17.11.

ATEC has been the subject of several research analyst reports. Barclays lifted their price objective on Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th. Needham & Company LLC restated a “buy” rating and set a $13.00 price target on shares of Alphatec in a report on Thursday, October 31st. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Thursday, October 31st. Lake Street Capital cut their target price on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Friday, August 30th.

Institutional Investors Weigh In On Alphatec

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Alphatec by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 5,458,847 shares of the medical technology company’s stock worth $75,278,000 after purchasing an additional 64,648 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Alphatec by 14.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 26,346 shares of the medical technology company’s stock worth $364,000 after buying an additional 3,268 shares in the last quarter. Comerica Bank raised its position in Alphatec by 64.8% in the 1st quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock valued at $89,000 after buying an additional 2,534 shares during the last quarter. Cetera Advisors LLC lifted its stake in Alphatec by 15.6% during the 1st quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company’s stock valued at $175,000 after acquiring an additional 1,720 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in Alphatec by 44.6% during the 2nd quarter. SG Americas Securities LLC now owns 14,495 shares of the medical technology company’s stock worth $151,000 after acquiring an additional 4,472 shares during the last quarter. 66.35% of the stock is owned by institutional investors.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $9.63 on Wednesday. The company has a market capitalization of $1.37 billion, a PE ratio of -7.52 and a beta of 1.38. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. Alphatec has a twelve month low of $4.88 and a twelve month high of $17.34. The firm has a fifty day simple moving average of $7.55 and a 200 day simple moving average of $8.14.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.